Sakuma Kaname, Tamura Ryuki, Noda Naoto, Mizutani Masutaka, Yamaguchi Akira, Tanaka Akira
Department of Oral and Maxillofacial Surgery, Niigata Hospital, The Nippon Dental University, Niigata 951-8580, Japan.
Department of Oral and Maxillofacial Surgery, The Nippon Dental University School of Life Dentistry at Niigata, Niigata 951-8580, Japan.
Mol Clin Oncol. 2017 Oct;7(4):637-641. doi: 10.3892/mco.2017.1367. Epub 2017 Aug 8.
anticancer drug sensitivity assessments have been performed for various types of cancer, and an association with clinical response has been observed. The collagen gel droplet-embedded culture drug sensitivity test (CD-DST) is an anticancer drug sensitivity test that has recently reported to be useful in oral squamous cell carcinoma (OSCC). CD-DST allows for the analysis of a smaller number of cells compared with other anticancer drug sensitivity tests. The present study reported a successful analysis of anticancer drug sensitivity using CD-DST on cervical lymph node tissue dissected following neoadjuvant chemotherapy from a 55-year-old man with advanced hard palate cancer. Tumor resection and bilateral neck dissection were performed following neoadjuvant chemotherapy (docetaxel + cisplatin + 5-fluorouracil; TPF) for hard palate cancer T2N2cM0. Local recurrence and cervical multiple skin metastasis occurred ~8 months after surgery, and the patient received six doses of cetuximab (C-mab) + cisplatin + 5-fluorouracil (C-mab + PF) administration, which is a type of molecular-targeted therapy. Following the use of the CD-DST method, the clinical response was noted as stable disease following execution of TPF and partial response following execution of C-mab + PF. In addition, low sensitivity by TPF and high sensitivity by C-mab + PF were reported. The CD-DST method reflected the clinical response for the patient, and the results of the current study indicate that CD-DST is a useful tool for selecting chemotherapeutic drugs for patients with OSCC.
已经对各种类型的癌症进行了抗癌药物敏感性评估，并观察到其与临床反应的相关性。胶原凝胶微滴包埋培养药物敏感性试验（CD-DST）是一种抗癌药物敏感性试验，最近报道其在口腔鳞状细胞癌（OSCC）中有用。与其他抗癌药物敏感性试验相比，CD-DST允许分析较少数量的细胞。本研究报告了对一名55岁晚期硬腭癌男性新辅助化疗后切除的颈部淋巴结组织使用CD-DST成功进行抗癌药物敏感性分析。硬腭癌T2N2cM0新辅助化疗（多西他赛+顺铂+5-氟尿嘧啶；TPF）后进行肿瘤切除和双侧颈清扫术。术后约8个月出现局部复发和颈部多发皮肤转移，患者接受了六剂西妥昔单抗（C-mab）+顺铂+5-氟尿嘧啶（C-mab+PF）给药，这是一种分子靶向治疗。使用CD-DST方法后，观察到TPF治疗后临床反应为疾病稳定，C-mab+PF治疗后为部分缓解。此外，报告了TPF的低敏感性和C-mab+PF的高敏感性。CD-DST方法反映了该患者的临床反应，本研究结果表明CD-DST是为OSCC患者选择化疗药物的有用工具。
